Bright Minds Biosciences (DRUG) Competitors $55.20 +4.37 (+8.60%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$54.08 -1.12 (-2.04%) As of 10/8/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. GPCR, SDGR, ABCL, JANX, RCUS, SNDX, ARDX, STOK, XERS, and ZYMEShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Structure Therapeutics (GPCR), Schrodinger (SDGR), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Structure Therapeutics Schrodinger AbCellera Biologics Janux Therapeutics Arcus Biosciences Syndax Pharmaceuticals Ardelyx Stoke Therapeutics Xeris Biopharma Zymeworks Structure Therapeutics (NASDAQ:GPCR) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has more risk & volatility, GPCR or DRUG? Structure Therapeutics has a beta of -1.65, suggesting that its stock price is 265% less volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -6.17, suggesting that its stock price is 717% less volatile than the S&P 500. Does the media prefer GPCR or DRUG? In the previous week, Bright Minds Biosciences had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 3 mentions for Structure Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.92 beat Structure Therapeutics' score of 0.53 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in GPCR or DRUG? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 5.6% of Structure Therapeutics shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend GPCR or DRUG? Structure Therapeutics currently has a consensus price target of $68.67, indicating a potential upside of 141.36%. Bright Minds Biosciences has a consensus price target of $81.00, indicating a potential upside of 46.74%. Given Structure Therapeutics' higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has better earnings and valuation, GPCR or DRUG? Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-27.10Bright Minds BiosciencesN/AN/A-$2.06M-$0.93-59.35 Is GPCR or DRUG more profitable? Bright Minds Biosciences' return on equity of -20.96% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Bright Minds Biosciences N/A -20.96%-20.66% SummaryBright Minds Biosciences beats Structure Therapeutics on 8 of the 13 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$358.05M$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-59.3521.5785.4727.60Price / SalesN/A427.64582.22224.03Price / CashN/A47.1237.9261.55Price / Book60.0010.1413.136.76Net Income-$2.06M-$52.31M$3.30B$275.88M7 Day Performance-1.43%5.14%4.29%2.81%1 Month Performance30.90%14.68%9.45%9.24%1 Year Performance5,135.20%30.98%86.64%35.42% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.0523 of 5 stars$55.20+8.6%$81.00+46.7%+5,011.1%$358.05MN/A-59.35N/AGPCRStructure Therapeutics3.0868 of 5 stars$25.30+1.2%$68.67+171.4%-29.8%$1.44BN/A-24.10136Analyst ForecastSDGRSchrodinger3.1994 of 5 stars$20.04+3.8%$27.83+38.9%+21.0%$1.42B$207.54M-8.08790Analyst ForecastABCLAbCellera Biologics2.6471 of 5 stars$4.87+2.7%$8.00+64.3%+140.1%$1.42B$28.83M-8.85500Analyst ForecastJANXJanux Therapeutics1.8078 of 5 stars$23.70+2.0%$78.31+230.4%-46.1%$1.40B$439K-13.1730Analyst ForecastRCUSArcus Biosciences1.8967 of 5 stars$13.34+3.9%$21.14+58.5%-13.8%$1.37B$258M-4.21500News CoverageAnalyst ForecastInsider TradeSNDXSyndax Pharmaceuticals3.75 of 5 stars$15.56-0.8%$39.22+152.1%-10.2%$1.35B$23.68M-4.00110Analyst ForecastAnalyst RevisionARDXArdelyx4.3134 of 5 stars$5.63+1.6%$11.70+107.8%-15.1%$1.34B$333.61M-24.4890News CoverageAnalyst ForecastSTOKStoke Therapeutics3.2444 of 5 stars$24.73+2.4%$25.57+3.4%+148.4%$1.32B$36.56M29.09100News CoverageAnalyst ForecastInsider TradeXERSXeris Biopharma2.8562 of 5 stars$8.08-1.2%$7.08-12.3%+178.9%$1.32B$203.07M-38.47290News CoveragePositive NewsAnalyst ForecastZYMEZymeworks2.0742 of 5 stars$17.23+3.8%$21.43+24.4%+33.1%$1.30B$122.87M-11.49460News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies Structure Therapeutics Competitors Schrodinger Competitors AbCellera Biologics Competitors Janux Therapeutics Competitors Arcus Biosciences Competitors Syndax Pharmaceuticals Competitors Ardelyx Competitors Stoke Therapeutics Competitors Xeris Biopharma Competitors Zymeworks Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
